The addition of a new distribution partner in Europe devoted to Ingevity's Capa biodegradable thermoplastics allows the company to better service its customers in the region. Ultrapolymers' network of compounders and converters, as well as its technical competence and customer service, are consistent with Ingevity's growth strategy in Europe. Image Source: Zacks Investment Research Ingevity, in February 2019, completed the purchase of the Capa caprolactone division of Perstorp Holding AB for roughly $652.5 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 ______________________ ...

For the quarter ended March 2024, Ingevity (NGVT) reported revenue of $340.1 million, down 13.4% over the same period last year. EPS came in at $0.52, compared to $1.09 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $319.85 million, representing a surprise of +6.33%. The company delivered an EPS surprise of +40.54%, with the consensus EPS estimate being $0.37.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

Ingevity (NGVT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $1.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 40.54%. A quarter ago, it was expected that this company would post a loss of $0.13 per share when it actually produced earnings of $0.21, delivering a surprise of 261.54%.Over the last four quarters, the company has surp ...

Exhibit 99.1 News Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com Contact: Caroline Monahan 843-740-2068 media@ingevity.com Investors: John E. Nypaver, Jr. 843-740-2002 investors@ingevity.com Ingevity reports first quarter 2024 financial results HIGHLIGHTS: (comparisons versus prior year period) The results and guidance in this release include non-GAAP financial measures. Refer to the section entitled "Use of non- GAAP financial measures" within this release ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ FORM 10-K ______________________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-375 ...

Financial Performance Summary - Full year net sales were up by 1.4% reaching $1,692.1 million compared to $1,668.3 million in the prior year[23] - Adjusted EBITDA for the full year declined by 12.3% to $396.8 million[23, 24] - Diluted adjusted EPS decreased by 34% to $3.94[23, 118] Segment Performance - Performance Materials' full year sales increased by 6.8% to $586.0 million[12] and segment EBITDA increased by 13.6% to $286.6 million[12] - Road Technologies' full year sales increased by over 53% due to increased technology adoption and the acquisition of Ozark road markings business, reaching $369.8 million[17, 31] - Advanced Polymer Technologies' full year sales decreased by 16.6% to $204.0 million[28] - Industrial Specialties' full year sales decreased by 16% to $532.3 million[31, 43] 2024 Guidance - The company expects revenue between $1.40 billion and $1.55 billion[19] - Adjusted EBITDA is projected to be between $365 million and $390 million[19] - Capital expenditures are estimated to be between $90 million and $110 million[19]

Exhibit 99.1 News Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com Contact: Caroline Monahan 843-740-2068 media@ingevity.com Investors: John Nypaver 843-740-2002 investors@ingevity.com Ingevity reports fourth quarter and full year 2023 financial results Fourth Quarter (comparisons versus prior year period): Full Year (comparisons versus prior year period): Guidance: Company announces full year 2024 guidance for sales between $1.40 billion and $1.55 billion an ...

Financial Performance - Net sales decreased by 7.5% to $446.0 million in Q3 2023 compared to $482.0 million in Q3 2022 [31] - Adjusted EBITDA decreased by 20.1% to $110.4 million with a margin of 24.8% in Q3 2023, compared to $138.2 million with a margin of 28.7% in Q3 2022 [31] - Diluted adjusted EPS decreased by 42.1% to $1.21 in Q3 2023, compared to $2.09 in Q3 2022 [31] - Performance Chemicals segment EBITDA decreased by 62% due to higher CTO costs and weak demand, reaching $24.7 million with a margin of 9.6% [4, 53, 59] Segment Performance - Performance Materials net sales increased by 1.6% to $147.2 million, with segment EBITDA up by 21.7% to $74.5 million and a margin of 50.6% [45] - Industrial Specialties sales decreased by 30% due to lower volumes, with segment EBITDA flat at $11.2 million and a margin of 26.2% [14, 42] - Pavement Technologies sales increased by 47% due to pricing gains and the Ozark acquisition [61] - Advanced Polymer Technologies (APT) sales decreased by 4% to $256.0 million due to lower volumes, with segment EBITDA margin improving to 26.2% [13, 14] Strategic Initiatives and Outlook - The company is repositioning its Performance Chemicals business to focus on higher margin specialty products, expecting EBITDA margins to improve from mid-single digits to 15-20% [30, 50] - The company expects approximately $180 million of non-cash charges and $100 million in cash charges related to the repositioning, with the majority of non-cash and 50-60% of cash charges recognized by the end of the first half of 2024 [8, 70] - The company anticipates ~$25 million in combined savings from Q2 actions and the repositioning announcement [48] - The company reduced total global headcount by approximately 20% [17] - The company expects revenue between $1.6 and $1.7 billion, adjusted EBITDA between $375 and $390 million, capital expenditures between $95 and $105 million, and free cash flow between $75 and $85 million for the full year [47]

PART I - FINANCIAL INFORMATION [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents Ingevity Corporation's unaudited Condensed Consolidated Financial Statements for the period ended September 30, 2023, including key notes on segment reporting changes and the planned DeRidder plant closure Condensed Consolidated Statements of Operations (Unaudited) | In millions, except per share data | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | **Net sales** | $446.0 | $482.0 | $1,320.4 | $1,284.7 | | **Gross profit** | $129.0 | $176.3 | $412.4 | $464.7 | | **Income (loss) before income taxes** | $32.1 | $95.8 | $143.9 | $249.9 | | **Net income (loss)** | $25.2 | $75.4 | $111.4 | $196.0 | | **Diluted earnings (loss) per share** | $0.69 | $1.98 | $3.03 | $5.06 | Condensed Consolidated Balance Sheets (Unaudited) | In millions | September 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Total Current assets** | $734.5 | $679.0 | | **Total Assets** | $2,766.8 | $2,736.5 | | **Total Current liabilities** | $305.1 | $303.5 | | **Total Liabilities** | $2,048.1 | $2,038.2 | | **Total Equity** | $718.7 | $698.3 | Condensed Consolidated Statements of Cash Flows (Unaudited) | In millions | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--- | :--- | :--- | | **Net cash provided by (used in) operating activities** | $160.5 | $214.9 | | **Net cash provided by (used in) investing activities** | $(56.3) | $(144.7) | | **Net cash provided by (used in) financing activities** | $(93.4) | $(264.9) | - In Q1 2023, the company realigned its segment reporting, creating the Advanced Polymer Technologies segment from Performance Chemicals and splitting the Performance Chemicals goodwill reporting unit[19](index=19&type=chunk) - On November 1, 2023, the company announced the permanent closure of its DeRidder, Louisiana manufacturing plant by H1 2024, anticipating approximately **$280.0 million** in aggregate charges, with about **$180.0 million** being non-cash[138](index=138&type=chunk)[139](index=139&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=29&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q3 and nine-month 2023 financial results, highlighting a 7.5% Q3 net sales decrease, gross profit impact from CTO inflation, Performance Chemicals repositioning, and full-year 2023 guidance of **$1.6-$1.7 billion** sales and **$375-$390 million** Adjusted EBITDA [Overview and Recent Developments](index=30&type=section&id=Overview%20and%20Recent%20Developments) The company announced strategic actions to reposition its Performance Chemicals segment, including the DeRidder plant closure with **$280 million** in expected charges, and a goodwill impairment test that concluded no impairment with a **19%** headroom - On November 1, 2023, Ingevity announced strategic actions to reposition its Performance Chemicals segment, including the permanent closure of its DeRidder, Louisiana plant by the end of H1 2024[147](index=147&type=chunk) - The company expects to incur approximately **$280.0 million** in aggregate charges related to these actions, with about **$180.0 million** being non-cash asset-related charges[148](index=148&type=chunk) - A goodwill impairment test for the Performance Chemicals reporting unit concluded no impairment, with the fair value exceeding the carrying value by **19%**[152](index=152&type=chunk) [Results of Operations](index=32&type=section&id=Results%20of%20Operations) Q3 2023 net sales decreased by **$36.0 million** (7.5%) due to volume declines, while nine-month net sales increased by **$35.7 million** (2.8%) due to price/mix improvements, with gross profit negatively impacted by CTO inflation in both periods Net Sales Variance Analysis (vs. Prior Year) | In millions | Prior Year Net Sales | Volume | Price/Mix | Currency Effect | Current Year Net Sales | | :--- | :--- | :--- | :--- | :--- | :--- | | **Q3 2023 vs 2022** | $482.0 | $(72.1) | $38.3 | $(2.2) | $446.0 | | **9M 2023 vs 2022** | $1,284.7 | $(97.1) | $142.4 | $(9.6) | $1,320.4 | - Q3 gross profit decreased by **$47.3 million**, primarily due to **$42.6 million** in increased manufacturing costs from CTO inflation and a **$36.7 million** negative impact from lower sales volume[160](index=160&type=chunk) - Restructuring and other charges increased to **$24.6 million** in Q3 2023 from **$3.3 million** in Q3 2022, mainly due to costs from the alternative fatty acid transition at the Crossett plant and the North Charleston plant transition[167](index=167&type=chunk) [Segment Operating Results](index=36&type=section&id=Segment%20Operating%20Results) In Q3 2023, Performance Materials saw sales and EBITDA growth, while Performance Chemicals experienced significant declines due to lower volumes and high CTO costs, and Advanced Polymer Technologies' sales fell but EBITDA remained flat Performance Materials Segment Results (Q3 2023 vs Q3 2022) | In millions | Q3 2023 | Q3 2022 | Change | | :--- | :--- | :--- | :--- | | **Net Sales** | $147.2 | $144.9 | +1.6% | | **Segment EBITDA** | $74.5 | $61.2 | +21.7% | Performance Chemicals Segment Results (Q3 2023 vs Q3 2022) | In millions | Q3 2023 | Q3 2022 | Change | | :--- | :--- | :--- | :--- | | **Net Sales** | $256.0 | $267.6 | -4.3% | | **Segment EBITDA** | $24.7 | $65.7 | -62.4% | Advanced Polymer Technologies Segment Results (Q3 2023 vs Q3 2022) | In millions | Q3 2023 | Q3 2022 | Change | | :--- | :--- | :--- | :--- | | **Net Sales** | $42.8 | $69.5 | -38.4% | | **Segment EBITDA** | $11.2 | $11.3 | -0.9% | [Current Full Year Company Outlook](index=39&type=section&id=Current%20Full%20Year%20Company%20Outlook) For full-year 2023, Ingevity projects net sales between **$1.6 billion** and **$1.7 billion**, with Adjusted EBITDA between **$375 million** and **$390 million**, reflecting segment-specific trends and CTO cost pressures - Full-year 2023 net sales are expected to be between **$1.6 billion** and **$1.7 billion**[205](index=205&type=chunk) - Full-year 2023 Adjusted EBITDA is expected to be between **$375 million** and **$390 million**[206](index=206&type=chunk) [Liquidity and Capital Resources](index=41&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains sufficient liquidity through operating cash flow, a new **$100.0 million** accounts receivable securitization program, and available credit, with projected 2023 capital expenditures of **$95-$105 million** and **$353.4 million** remaining for share repurchases - On October 2, 2023, the company entered into a **$100.0 million** accounts receivable securitization program to provide additional liquidity[211](index=211&type=chunk) - During the first nine months of 2023, the company repurchased **$92.1 million** of its common stock, with **$353.4 million** remaining available under the share repurchase program as of September 30, 2023[213](index=213&type=chunk) - Projected capital expenditures for the full year 2023 are between **$95 million** and **$105 million**[215](index=215&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=43&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces market risks from foreign currency fluctuations, interest rate changes on variable-rate debt, and commodity price volatility, with Crude Tall Oil (CTO) representing approximately **25%** of consolidated cost of sales in the first nine months of 2023 - A hypothetical **10%** adverse change in euro and Chinese renminbi exchange rates would have decreased net sales by approximately **$13.2 million** for the nine months ended September 30, 2023[225](index=225&type=chunk) - A hypothetical **100 basis point** increase in variable interest rates would have increased annual interest expense by approximately **$8.3 million** based on debt levels for the nine months ended September 30, 2023[226](index=226&type=chunk) - Crude Tall Oil (CTO) represented about **25%** of consolidated cost of sales for the first nine months of 2023, and a hypothetical **10%** increase in its market price would have increased cost of sales by approximately **$22 million**[228](index=228&type=chunk) [Controls and Procedures](index=44&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded the company's disclosure controls and procedures were effective as of September 30, 2023, following the completion of a new global ERP system implementation in early 2023 that updated processes and internal controls - The CEO and CFO concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2023[231](index=231&type=chunk) - The company completed the final phase of its new global ERP system implementation in early 2023, leading to changes in processes and internal controls over financial reporting[232](index=232&type=chunk) PART II - OTHER INFORMATION [Legal Proceedings](index=45&type=section&id=Item%201.%20Legal%20Proceedings) This section details ongoing litigation with BASF, where a jury awarded approximately **$85.0 million** (trebled under antitrust law), which Ingevity has accrued but intends to appeal - In the legal proceeding with BASF, a jury awarded damages of approximately **$28.3 million**, trebled to approximately **$85.0 million** under U.S. antitrust law[116](index=116&type=chunk) - The company has accrued the full **$85.0 million** verdict in 'Other liabilities' but disagrees with the outcome and is actively seeking to have it set aside or overturned on appeal[117](index=117&type=chunk)[118](index=118&type=chunk) [Risk Factors](index=45&type=section&id=Item%201A.%20Risk%20Factors) This section introduces new material risk factors, primarily concerning the planned closure of the DeRidder, Louisiana plant and the cessation of critical services from WestRock's North Charleston paper mill, both posing potential operational and financial impacts - A new risk factor is the closure of the DeRidder, Louisiana plant, with potential negative impacts including costs exceeding estimates, adverse legal actions, and financial losses from excess CTO inventory[237](index=237&type=chunk) - A new risk factor stems from the closure of WestRock's North Charleston paper mill, which provided critical services to Ingevity's plant, potentially causing operational interruptions and significant capital expenditure to replace them[238](index=238&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=45&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details the company's stock repurchase activity, noting no repurchases during Q3 2023, with approximately **$353.4 million** remaining available under the board-authorized program as of September 30, 2023 Issuer Purchases of Equity Securities (Q3 2023) | Period | Total Number of Shares Purchased | Average Price Paid Per Share | Approximate Dollar Value of Shares that May Yet be Purchased Under the Plan | | :--- | :--- | :--- | :--- | | July 2023 | — | $ — | $353,384,633 | | August 2023 | — | $ — | $353,384,633 | | September 2023 | — | $ — | $353,384,633 | | **Total** | **—** | **$ —** | **$353,384,633** | [Defaults Upon Senior Securities](index=46&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This section is not applicable [Mine Safety Disclosures](index=46&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section is not applicable [Other Information](index=46&type=section&id=Item%205.%20Other%20Information) This section contains no additional information [Exhibits](index=47&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including certifications by the Principal Executive Officer and Principal Financial Officer, and the Inline XBRL instance document